FDA Escalates Tomato Recall Over Lethal Risk—Here's What to Know
An ongoing recall of tomatoes has now been upgraded to Class I, the highest level of warning by the Food and Drug Administration (FDA), due to a higher probability of severe illness or even death.
South Carolina-based Williams Farms Repack LLC initiated a recall of several sizes of tomatoes over possible salmonella contamination, according to an announcement by the FDA on May 2.
The tomatoes were distributed between April 23 and 28 to Georgia, North Carolina, and South Carolina. The affected products were available in multiple packaging formats with either the Williams Farms Repack label or H&C Farms label:
5x6 25 pounds, lot code: R4467
6x6 25 pounds, lot codes: R4467, R4470
Combo 25 pounds, lot code: R4467
4x4 2 layer, lot code: R4467
4x5 2 layer, lot code: R4467
60-count, 2 layer, lot code: R4467
60-count, 18 pounds, loose, lot codes: R4467, R4470
XL, 18 pounds, loose, lot code: R4467
3-count trays with UPC 0 33383 65504 8, lot code: R4467
The FDA has since designated the recall as Class I, warning that exposure may lead to serious or fatal health outcomes. A Class I recall is "a situation where there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the agency.
Salmonella infections can cause symptoms within six hours to six days of consuming the contaminated food. These symptoms include diarrhea, abdominal cramps, nausea, and vomiting, as well as a fever, chills, and dehydration. Symptoms typically last four to seven days but may persist longer if complications arise.
While the majority of salmonella infections are mild and resolve on their own, they can pose serious health risks, especially to vulnerable groups such as infants, the elderly, pregnant women, and those with weakened immune systems, according to the FDA.
While the tomatoes should no longer be available in stores, the FDA states that the bacteria can survive for weeks in dry environments and months in wet ones, so check to see if you still have the recalled produce in your home and discard it immediately. Products may be returned for a full refund.
Read the original article on Martha Stewart
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
28 minutes ago
- New York Times
F.D.A. Looks to A.I. to Enhance Efficiency
The Food and Drug Administration is planning to use artificial intelligence to 'radically increase efficiency' in deciding whether to approve new drugs and devices, one of several top priorities laid out in an article published Tuesday in JAMA. Another initiative involves a review of chemicals and other 'concerning ingredients' that appear in U.S. food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count. 'The F.D.A. will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children and common-sense approaches to rebuild the public trust,' Dr. Marty Makary, the agency commissioner, and Dr. Vinay Prasad, who leads the division that oversees vaccines and gene therapy, wrote in the JAMA article. The agency plays a central role in pursuing the agenda of the U.S. health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that artificial intelligence is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. 'I don't want to be dismissive of speeding reviews at the F.D.A.,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' Want all of The Times? Subscribe.
Forbes
31 minutes ago
- Forbes
Another Deadly Cancer That's Potentially Been Tamed By Globalization
'In my 30 years of oncology, we haven't talked about curing myeloma.' Those are the words of University of North Carolina professor of cancer policy, Norman Sharpless, as reported in the New York Times. For those who don't know, multiple myeloma is a blood cancer that's long been known as incurable. Which raises a question: what would readers do if they received a multiple myeloma diagnosis? It's no reach to say that most of us would ask the doctor relaying the horrible news if there's any hope, any cure, or any possible cure anywhere. This would particularly be true with myeloma since the traditional path to death within a year of diagnosis is described by the Times as 'extremely painful.' Enter Legend Biotech, a Somerset, NJ biotechnology company. The Times reports that the immunotherapy developed there loomed as a 'last-ditch' option five years ago for close to 100 myeloma patients. The encouraging, beautiful news is that a third emerged from what was traditionally a death sentence alive and cancer free. To say that what's happening at Legend Biotech is an exciting development insults understatement. Finally, after all this time there's progress. And the progress exists as optimism that we're on the doorstep of many more remarkable leaps. Which requires another pause. Though Legend is based in Somerset, NJ, its origins are Chinese. It raises a question: would readers facing death refuse the treatments developed by Legend, or some other pharmaceutical corporation operating in China? One assumes the question answers itself. On matters of life and death, there's a natural tendency among humans to do whatever it takes to survive, particularly if they have children. It's just a comment that when death stares us in the face, no pause is required. We're wired to search far and wide for whatever will keep us upright. The main thing is that while Legend is now New Jersey-based, it still has operations in China. Good. The more that the world is economically integrated, the better off we all are. In other words, it's not a 'national security' threat when great leaps of the AI, financial, or pharmaceutical variety are hatched somewhere not the United States. Figure that if trading lanes are open, it's as though the world's greatest products, services and cures are all being created right next door. And when market goods are crossing borders without regard to country origin, war of the shooting and bombing kind becomes frightfully expensive. Looked at in tax terms, Legend's global footprint is hopefully a reminder to U.S. tax writers that when it comes to innovative developments meant to cure some of the worst diseases, it's extraordinarily mistaken to tax 'Made in America' more favorably than 'Made Around the World.' The more that U.S. pharmaceutical companies avail themselves of global talent, the much better that American drugs will be. And the more that tax policy is neutral as applied to U.S. corporations, the more easily they'll be able to acquire the best of the best globally. The simple, and ultimately life-saving truth is that productivity is an effect of cooperation across as many hands, machines, and machines that think as possible. Drugs aren't unique in this regard. The more specialized cooperation in the development of moon-shot style cures, the quicker the arrival at the cure. Sharpless went on to tell the Times that 'This is the first time we are really talking seriously about cures in one of the worst malignancies imaginable.' The brilliant fruits of tessellated talents at opposite sides of the world. It's just something to remember. Cliched though it may sound, there's no limit to progress when specialized genius is combined. Let's not allow tax writers to erect barriers to this collaboration solely because genius occasionally has a foreign address.
Bloomberg
an hour ago
- Bloomberg
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.
